A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

Starting soon · Not applicable

Conditions studied: Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine, Medication Adherence

In brief

This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved personalized support and increase medication adherence for people with AUD and ALD.

Key facts

Study ID

NCT07553377

Run by

Yale University

People needed

50

Starts

2027-10-01

Expected to finish

2030-10-01

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Being treated for AUD
• Diagnosed with DSM-5 moderate to severe AUD
• Screens positive ALD utilizing non-invasive blood tests
• Planned initiation of acamprosate

You may not qualify if…

• History of hypersensitivity to acamprosate
• Allergy to magnesium or silver
• Severe renal impairment (creatinine clearance of 30mL/min or less)

Where it is running

• Yale — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.